Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZUMA-2 Cohort 3: Brexucabtagene Autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
2023-506641-35-00Phase 2Completed
- Sponsor
- Kite Pharma
- Start
- Dec 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of brexucabtagene autoleucel in mantle cell lymphoma (MCL), sponsored by Kite Pharma. Primary endpoint: Overall response rate (ORR) per IRRC. Started Dec 2023; status: completed.
02
Drugs
brexucabtagene autoleucel
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2023-506641-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506641-35-00.